首页 > 市场调查报告书 > 医疗设备

感测器生技设备

市场调查报告书

商品编码

1733220

2026 年至 2032 年生物感测器市场类型、应用、技术、最终用户和地区分析

Biosensors Market By Type (Wearable, Implantable), Application (Medical Diagnostics, Food Analysis), Technology (Electrochemical, Optical), End-Users (Hospitals & Clinics, Diagnostic Laboratories), & Region for 2026-2032

出版日期: 2025年04月30日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3个工作天内

价格

简介目录

2026-2032年生物感测器市场评估

奈米技术和微电子技术的创新正在提高灵敏度和特异性，促进生物感测器的采用。慢性病的增加将推动对生物感测器提供的持续监测解决方案的需求，使市场规模在 2024 年超过 333 亿美元，并在 2032 年达到约 605 亿美元的估值。

此外，医疗保健基础设施和研发方面的投资不断增加，推动了先进生物感测技术的发展，刺激了生物感测器的普及。对照护现场诊断的需求不断增长，推动了可携式和易于使用的生物感测器的采用，2026 年至 2032 年的复合年增长率为 8.55%。

生物感测器市场定义/概述

生物感测器是一种将生物反应转换为电讯号的分析装置，可以检测和量化各种物质。生物感测器通常由生物检验元件（例如酶、抗体或微生物）和将生化相互作用转换为可测量讯号的换能器组成。该技术可提供快速、灵敏和特异性的分析，使其在各个领域都具有价值。

生物感测器的应用范围广泛且多样。在医疗保健领域，它们用于监测糖尿病患者的血糖浓度、检测病原体以及进行照护现场诊断。环境监测也是一个重要领域，生物感测器可以检测水和土壤中的污染物和病原体，有助于确保公共和环境保护。此外，生物感测器还用于食品安全，可以快速检测污染物并确保食品品质。

劳动力管理如何提高生物感测器的采用率？

慢性病盛行率的上升以及对快速且准确诊断解决方案的需求不断增长，推动着生物感测器市场的发展。根据世界卫生组织 (WHO) 的《2023 年全球健康报告》，糖尿病影响全球约 5.37 亿成年人，推动了对用于持续血糖监测的生物感测器的需求。人工智慧和物联网功能的整合透过即时数据分析和远端患者监护彻底改变了疾病监控和管理。随着雅培实验室于 2024 年 3 月推出新款 FreeStyle Libre 4 系统，这一趋势进一步增强，该系统具有更高的准确性和智慧型手机连接性，可用于糖尿病管理。

COVID-19 疫情加速了医疗保健领域对就地检验和生物感测器技术的采用。美国疾病管制与预防中心报告称，到2023年，利用生物感测器技术的快速诊断测试与传统实验室检测方法相比，平均诊断时间缩短了65%。对早期疾病检测和预防性医疗保健的重视正在推动对生物感测器研究和开发的大量投资。 2024年2月，罗氏诊断推出了其最新的用于心臟生物标记检测的生物感测器平台。

环境监测和食品安全问题已成为采用生物感测器技术的主要驱动力。欧洲食品安全局 2023 年的报告显示，基于生物感测器的食品检测方法检测污染物的速度比传统检测方法快 40%。微型和携带式生物感测器的发展正在扩大其在从农业到环境保护等各个行业的应用。赛默飞世尔科技于 2024 年 1 月收购了主要企业，并推出了用于环境污染物检测的新型多路復用生物感测器平台，突显了这一市场变革。

缺乏标准化测试和品管措施是否会抑制生物感测器市场的成长？

资料管理和互通性问题也带来了挑战。随着生物感测器产生的数据量越来越大，确保有效的数据整合和分析将变得至关重要。许多医疗保健提供者和实验室难以管理这些数据，尤其是在将生物感测器整合到现有系统时，这可能会阻碍临床应用。

另一个主要限制因素是监管核准流程的复杂性。生物感测器，尤其是用于医疗应用的生物感测器，必须经过严格的测试和检验，以满足安全性和有效性的标准。这个漫长而昂贵的核准过程减缓了新生物感测器产品的市场推广，并抑制了投资和创新。

此外，整个生物感测器产业缺乏标准化测试和品管措施。如果没有标准化的协议，製造商就很难确保产品的可靠性和可重复性。这种不一致性可能会导致使用者和医疗保健专业人员对生物感测器的性能产生怀疑，从而减缓市场接受度。

Innovations in nanotechnology and microelectronics enhance the sensitivity and specificity is propelling the adoption of biosensors. Increasing prevalence of chronic diseases drives demand for continuous monitoring solutions provided by biosensors is driving the market size surpass USD 33.3 Billion valued in 2024 to reach a valuation of around USD 60.5 Billion by 2032.

In addition to this, increased investment in healthcare infrastructure and research fuels the development of advanced biosensing technologies is spurring up the adoption of biosensors. Rising demand for point-of-care diagnostics drives the adoption of portable and user-friendly biosensors is enabling the market to grow at a CAGR of 8.55% from 2026 to 2032.

Biosensors Market: Definition/Overview

Biosensors are analytical devices that convert a biological response into an electrical signal, allowing for the detection and quantification of various substances. They typically consist of a biological sensing element, such as enzymes, antibodies, or microorganisms, integrated with a transducer that converts the biochemical interaction into a measurable signal. This technology offers rapid, sensitive, and specific analysis, making it invaluable in various fields.

The applications of biosensors are vast and diverse. In healthcare, they are used for monitoring glucose levels in diabetic patients, detecting pathogens, and conducting point-of-care diagnostics. Environmental monitoring is another critical area, where biosensors can detect pollutants and pathogens in water and soil, helping to ensure public safety and environmental protection. Additionally, biosensors find uses in food safety, allowing for the rapid testing of contaminants and ensuring the quality of food products.

How will Workforce Management Increase Adoption of Biosensors?

The rising prevalence of chronic diseases and the growing demand for rapid, accurate diagnostic solutions have significantly propelled the biosensors market forward. According to the World Health Organization's 2023 Global Health Report, diabetes affects approximately 537 million adults worldwide, driving the need for continuous glucose monitoring biosensors. The integration of artificial intelligence and IoT capabilities has revolutionized disease monitoring and management through real-time data analysis and remote patient monitoring. This trend gained momentum when Abbott Laboratories launched their new FreeStyle Libre 4 system in March 2024, featuring enhanced accuracy and smartphone connectivity for diabetes management.

The COVID-19 pandemic has accelerated the adoption of point-of-care testing and biosensor technology across healthcare settings. The U.S. Centers for Disease Control and Prevention reported that rapid diagnostic tests utilizing biosensor technology reduced average diagnosis time by 65% in 2023 compared to traditional laboratory testing methods. The emphasis on early disease detection and preventive healthcare has driven substantial investments in biosensor research and development. In February 2024, Roche Diagnostics introduced their latest biosensor platform for cardiac biomarker detection, offering results in under 8 minutes with improved sensitivity.

Environmental monitoring and food safety concerns have emerged as crucial drivers for biosensor technology adoption. The European Food Safety Authority's 2023 report indicated that biosensor-based food testing methods detected contaminants 40% faster than conventional testing approaches. The development of miniaturized, portable biosensors has expanded their applications across various industries, from agriculture to environmental protection. This market evolution was highlighted when Thermo Fisher Scientific announced in January 2024 its acquisition of a leading biosensor technology company and the launch of their new multiplex biosensor platform for environmental pollutant detection.

Will Lack of Standardized Testing and Quality Control Measures Restraining Biosensors Market Growth?

Data management and interoperability issues also present challenges. As biosensors increasingly generate large volumes of data, ensuring effective data integration and analysis becomes crucial. Many healthcare providers and laboratories struggle with managing this data, particularly when integrating biosensors with existing systems, which can hinder their adoption in clinical settings.

Another significant restraint is the complexity of regulatory approval processes. Biosensors, especially those used in medical applications, must undergo rigorous testing and validation to meet safety and efficacy standards. This lengthy and often costly approval process can slow down the introduction of new biosensor products into the market, deterring investment and innovation.

Additionally, there is a lack of standardized testing and quality control measures across the biosensor industry. Without standardized protocols, it can be difficult for manufacturers to ensure the reliability and reproducibility of their products. This inconsistency can lead to skepticism among users and healthcare professionals regarding the performance of biosensors, slowing market acceptance.

Category-Wise Acumens

Will Rise in Adoption of Non-Wearable Biosensor Drive Biosensors Market Growth?

The non-wearable biosensor segment dominates the market, primarily driven by its widespread application in clinical diagnostics and laboratory settings. According to the National Institutes of Health's 2023 Medical Device Report, non-wearable biosensors accounted for 65% of all biosensor implementations in healthcare facilities, demonstrating their crucial role in diagnostic procedures. These devices offer superior sensitivity and specificity compared to their wearable counterparts, making them indispensable for accurate disease detection and monitoring. The segment's growth was further emphasized when Siemens Healthineers launched their advanced non-wearable biosensor platform in March 2024, featuring multiplexed detection capabilities for various biomarkers.

Point-of-care testing applications have significantly boosted the adoption of non-wearable biosensors in emergency departments and primary care settings. The U.S. Food and Drug Administration reported that non-wearable biosensor-based diagnostic tests reduced patient waiting times by 75% in 2023 compared to traditional laboratory methods. These devices enable rapid decision-making and immediate treatment initiation, particularly crucial in critical care scenarios. This trend was highlighted when Medtronic introduced its new non-wearable biosensor system in February 2024, designed for rapid cardiac biomarker detection with enhanced accuracy and reduced analysis time.

Will Rise in Adoption of Electrochemical Biosensors fuel Growth of Biosensors Market?

Electrochemical biosensors have established dominance in the market due to their exceptional sensitivity, cost-effectiveness, and rapid response capabilities in detecting biological analytes. The National Institute of Standards and Technology reported in 2023 that electrochemical biosensors demonstrated a 95% accuracy rate in glucose monitoring applications, significantly higher than other biosensor technologies. Their ability to provide quantitative results with minimal sample preparation has made them indispensable in clinical diagnostics and point-of-care testing. This technological advancement was highlighted when Dexcom introduced its next-generation electrochemical continuous glucose monitoring system in March 2024, featuring enhanced accuracy and extended sensor life.

The versatility of electrochemical biosensors in detecting various biomarkers has driven their widespread adoption in medical diagnostics and disease monitoring. According to the U.S. Food and Drug Administration's 2023 Medical Device Report, electrochemical biosensors accounted for 70% of all approved biosensor-based diagnostic devices. These sensors excel in providing real-time, label-free detection of biomolecules with high specificity. In February 2024, Roche Diagnostics launched their innovative electrochemical biosensor platform for cardiac biomarker detection, incorporating advanced electrode materials and improved signal processing capabilities.

Country/Region Wise Acumens

Will Advanced Healthcare Infrastructure in North America Bolster Expansion of Biosensors Market?

North America maintains its leadership position in the biosensors market, driven by advanced healthcare infrastructure and substantial investments in medical technology research and development. The U.S. Centers for Disease Control and Prevention reported in 2023 that biosensor adoption in American healthcare facilities increased by 45% compared to the previous year, highlighting the region's rapid technological integration. The presence of major market players and favorable regulatory frameworks has accelerated innovation in biosensor technology. This dominance was further solidified when Dexcom announced in March 2024 a USD 500 Million investment in expanding its biosensor manufacturing facilities across the United States, focusing on next-generation continuous glucose monitoring systems.

The region's robust pharmaceutical and biotechnology sectors have significantly contributed to biosensor market growth. According to the National Institutes of Health's 2023 Biomedical Research Report, North American institutions accounted for 55% of global biosensor-related patents and research publications. The increasing prevalence of chronic diseases and the growing demand for point-of-care diagnostics continue to drive market expansion. In February 2024, Abbott Laboratories secured FDA approval for their latest biosensor platform, featuring enhanced sensitivity for multiple biomarker detection and improved connectivity options for remote patient monitoring.

Will Rising Technological Advancements and Research Collaborations Enhance Adoption of Biosensors in Asia Pacific?

The Asia Pacific biosensors market is experiencing rapid growth, driven by increasing healthcare expenditure, rising chronic disease prevalence, and growing awareness of point-of-care diagnostics. Countries like China, Japan, and India are at the forefront of this expansion, with their large populations and improving healthcare infrastructure. According to a report by the World Health Organization, the Asia Pacific region accounted for 37% of the global medical devices market in 2020, indicating a strong foundation for biosensor adoption.

Technological advancements and research collaborations are further propelling the market forward. Universities and research institutions across the region are partnering with industry leaders to develop innovative biosensor technologies. For instance, in March 2024, the National University of Singapore announced a breakthrough in developing a highly sensitive graphene-based biosensor for rapid detection of infectious diseases. This innovation has the potential to revolutionize disease diagnosis and management in the region.

Competitive Landscape

The biosensors market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the biosensors market include:

Abbott Laboratories
Siemens Healthineers
Roche Diagnostics
Medtronic
Honeywell International, Inc.
Danaher Corporation
Johnson & Johnson
Thermo Fisher Scientific, Inc.
GlaxoSmithKline plc
Bayer AG
GE Healthcare
Sensirion AG
Molecular Devices (A part of Danaher)
Bio-Rad Laboratories, Inc.
Schott AG
Analytik Jena AG
Eppendorf AG
Novartis AG
Acon Laboratories, Inc.
Zymergen, Inc.
Biosensors Market Latest Developments
In October 2023, BioTech Innovations announced a partnership with HealthSense Technologies to develop advanced biosensors for real-time health monitoring, focusing on chronic disease management.
In September 2023, researchers at Stanford University unveiled a groundbreaking biosensor capable of detecting multiple biomarkers from a single drop of blood, aiming for faster diagnostic capabilities in clinical settings.

1 INTRODUCTION OF GLOBAL BIOSENSORS MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL BIOSENSORS MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL BIOSENSORS MARKET, BY TYPE

5.1 Overview
5.2 Wearable
5.3 Implantable
5.4 Non-Wearable

6 GLOBAL BIOSENSORS MARKET, BY END-USERS

6.1 Overview
6.2 Hospitals & Clinics
6.3 Diagnostic Laboratories
6.4 Food & Beverage
6.5 Environmental Monitoring Agencies
6.6 Pharmaceutical & Biotechnology Companies
6.7 Research Institutes & Academia

7 GLOBAL BIOSENSORS MARKET, BY TECHNOLOGY

7.1 Overview
7.2 Electrochemical
7.3 Optical
7.4 Piezoelectric
7.4 Thermal
7.5 Nanomechanical

8 GLOBAL BIOSENSORS MARKET, BY APPLICATION

8.1 Overview
8.2 Medical Diagnostics
8.3 Food Analysis
8.4 Environmental Monitoring
8.5 Industrial Process Control
8.6 Agricultural Testing, Biodefense

9 GLOBAL BIOSENSORS MARKET, BY GEOGRAPHY

9.1 Overview
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
- 9.2.3 Mexico
9.3 Europe
- 9.3.1 Germany
- 9.3.2 U.K.
- 9.3.3 France
- 9.3.4 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Rest of Asia Pacific
9.5 Rest of the World
- 9.5.1 Latin America
- 9.5.2 Middle East and Africa

10 GLOBAL BIOSENSORS MARKET COMPETITIVE LANDSCAPE

10.1 Overview
10.2 Company Market Ranking
10.3 Key Development Strategies

11 COMPANY PROFILES

11.1 Abbott Laboratories
- 11.1.1 Overview
- 11.1.2 Financial Performance
- 11.1.3 Product Outlook
- 11.1.4 Key Developments
11.2 Siemens Healthineers
- 11.2.1 Overview
- 11.2.2 Financial Performance
- 11.2.3 Product Outlook
- 11.2.4 Key Developments
11.3 Roche Diagnostics
- 11.3.1 Overview
- 11.3.2 Financial Performance
- 11.3.3 Product Outlook
- 11.3.4 Key Developments
11.4 Medtronic
- 11.4.1 Overview
- 11.4.2 Financial Performance
- 11.4.3 Product Outlook
- 11.4.4 Key Developments
11.5 Honeywell International, Inc.
- 11.5.1 Overview
- 11.5.2 Financial Performance
- 11.5.3 Product Outlook
- 11.5.4 Key Developments
11.6 Danaher Corporation
- 11.6.1 Overview
- 11.6.2 Financial Performance
- 11.6.3 Product Outlook
- 11.6.4 Key Developments
11.7 LifeSensors Inc.
- 11.7.1 Overview
- 11.7.2 Financial Performance
- 11.7.3 Product Outlook
- 11.7.4 Key Developments
11.8 Johnson & Johnson
- 11.8.1 Overview
- 11.8.2 Financial Performance
- 11.8.3 Product Outlook
- 11.8.4 Key Developments
11.9 Thermo Fisher Scientific, Inc.
- 11.9.1 Overview
- 11.9.2 Financial Performance
- 11.9.3 Product Outlook
- 11.9.4 Key Developments